Briefly
Jul 29, 2016

Second Quarter 2016 Financial Results

Double-digit revenue and adjusted EPS growth for the 6th consecutive quarter
 
Stories
Jul 18, 2016

How to Overcome the Blood-Brain Barrier to Deliver New Medicines

The brain’s protection barrier prevents medicines from getting in, but new approaches are finding ways to bust through and treat central nervous system diseases.

Briefly
Jul 11, 2016

Supporting Research to Help People with Neglected Tropical Diseases

A new Harvard case study examines why AbbVie works on Neglected Tropical Diseases (NTDs) in alliance with key nonprofits.

 
Stories
Jul 11, 2016

Immunotherapy: A Conversation with Steve Davidsen and Diane Hollenbaugh

As immunotherapies become a new and promising way to target cancer we examine what we know so far.

Stories
Jul 11, 2016

From Friend to Foe: When Your Immune System Turns Against You and How to Turn it Back

The immune system can go haywire in autoimmune diseases and cancer. While this may affect the body in different ways, the key to treating these diseases is interconnected. 

Briefly
Jul 01, 2016

Pediatric Outreach Strong in Romania and Malawi

AbbVie and Baylor College of Medicine team up again to renovate and expand children’s health facilities in Romania and Africa.

 
Stories
Jul 01, 2016

For Veterans Who’ve Served Others, An Opportunity To Be Served

Homecoming for some military veterans doesn’t always include a home. Employment, health and other challenges may create instability for new veterans and their families.
 

Briefly
Jun 24, 2016

Employee Outreach Making a Difference in Communities

AbbVie employees make a global effort to improve underserved communities during Week of Possibilities.  
 

VIEW ALL STORIES

PRESS RELEASES

Jul 29, 2016

AbbVie Reports Second-Quarter 2016 Financial Results

NORTH CHICAGO, Ill., July 29, 2016 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2016.

Jul 28, 2016

AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

NORTH CHICAGO, Ill., July 28, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of a Phase 3 clinical trial to study the safety and efficacy of venetoclax in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and have received one to three prior lines of therapy. The combination of venetoclax, bortezomib and dexamethasone will be compared to treatment with bortezomib, dexamethasone and placebo.1 Bortezomib, a proteasome inhibitor, and dexamethasone, a corticosteroid, are both common therapies used to treat symptomatic multiple myeloma.3  

Jul 25, 2016

AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C

NORTH CHICAGO, Ill., July 25, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) extended-release tablets. VIEKIRA XR is a once-daily, extended-release co-formulation of the active ingredients in VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) and is for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis (Child-Pugh A). VIEKIRA XR is not for people with decompensated cirrhosis.

MORE PRESS RELEASES